Hi all,
MPL is a fourth generation rapalog of Rapamycin with better autophagy ( clearing of dead cells ) and far less side effects.
MND is caused by protein aggregation at synapses of the brain causing dysfunction of nerve impulses.
This very recent study shows excellent results of reduction in cell death by clearing of said proteins. It was a 28 day study. Ours will be ongoing for months. Something to look forward to.
The author says Rapamycin is an ideal candidate for MND ALS therapy.
Ref : A microfluidic approach to rescue ALS motor neurones degeneration using Rapamycin . Chennampally Sept 2021.
PAA 2022 , Human Trials , Covid , MND , Oncology , HVTL-1, K9 Phase III, page-53
-
- There are more pages in this discussion • 1,414 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
20.5¢ |
Change
0.005(2.50%) |
Mkt cap ! $99.71M | |||
| Open | High | Low | Value | Volume |
| 20.5¢ | 20.5¢ | 20.0¢ | $66.86K | 327.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 27750 | 20.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.5¢ | 84999 | 3 |
View Market Depth
| Last trade - 14.42pm 27/09/2024 (20 minute delay) ? |
| PAA (ASX) Chart |